- Case report
- Open Access
Exacerbation of myopathy triggered by antiobesity drugs in a patient with multiple acyl-CoA dehydrogenase deficiency
BMC Neurology volume 21, Article number: 93 (2021)
Multiple acyl-CoA dehydrogenase deficiency (MADD) is a treatable lipid metabolism disorder that presents as myopathy and episodic metabolic crisis. The metabolic crisis is typically associated with prolonged fasting or physical stress; however, the mechanism of metabolic crisis is not yet fully understood.
A 28-year-old Taiwanese woman presented with dyspnoea, poor appetite, and muscle weakness after using antiobesity drugs, including metformin, triiodothyronine, and topiramate. MADD was diagnosed, and her symptoms rapidly improved after treatment with riboflavin, carnitine, and ubiquinone. To date, antiobesity drugs have not been reported to be a provoking factor in fatty acid oxidation disorder.
The increase of β-oxidation activity due to antiobesity drugs supports the hypothetical substrate competition model for MADD metabolic crisis. Because the drugs our patient used are commonly prescribed, we report this case to increase the vigilance and proactivity of clinicians in recognising this treatable adult-onset myopathy.
Multiple acyl-CoA dehydrogenase deficiency (MADD) is a lipid metabolism disorder caused by defects in electron transfer flavoprotein or electron transfer protein dehydrogenase, encoded by ETFA, ETFB, and ETFDH. MADD is the most prevalent lipid storage disease in Taiwan, where the hotspot mutation ETFDH c.250G > A has a carrier frequency of 0.8% . Patients with late-onset MADD typically present with lipid storage myopathy and episodic metabolic crisis. Metabolic crisis is usually associated with prolonged fasting or physical stress and manifests as the exacerbation of weakness, lethargy, vomiting, hypoketotic hypoglycaemia, and metabolic acidosis. The mechanism of metabolic crisis is not yet fully understood. Herein, we report the case of a patient with late-onset MADD who had an episodic exacerbation of muscle weakness after taking antiobesity drugs. This provoking factor has yet to be addressed in the literature. All possible mechanisms were reviewed and discussed. This report was approved by the Institutional Review Board of National Cheng Kung University Hospital (IRB Approval No. A-EC-108-009).
The 28-year-old Taiwanese woman whose condition is reported herein had an uneventful birth and developmental history. She exhibited suboptimal performance in exercise since elementary school age, especially in long-distance running. She experienced one episode of reversible proximal limb weakness for 3 days when she was 21 years old. She denied any weakness at baseline. She used antiobesity drugs, and in the preceding 4 months, her body weight decreased from 60 to 47 kg, with a corresponding reduction in body mass index from 22.3 to 17.5. The regimen of antiobesity drugs included metformin, triiodothyronine, topiramate, pseudoephedrine, hydrochlorothiazide, fluoxetine, and oxazolam. She was not prescribed diet change or caloric restriction. After weight loss, she exhibited poor appetite; poor oral intake; dyspnoea on exertion; and progressive weakness and soreness in the four proximal limbs, the neck, and the trunk. She was aided by a wheelchair upon admission.
On examination, the patient had intermittent tachycardia and dyspnoea on minimal exertion but had otherwise normal vital signs. She had reduced muscle strength in the proximal limbs (manual muscle power: bilateral deltoid: 3; bilateral finger abduction: 5; bilateral hip flexion: 4; bilateral dorsiflexion: 5), neck, and trunk, with positive Gowers’ sign and myopathic gait. Generalised muscle wasting involving the neck, trunk, shoulder girdle, pelvic girdle, and proximal and distal limbs but not the facial muscles was observed (Fig. 1a-c). No percussion myotonia was noted. The patient had mildly decreased memory and calculation abilities compared with healthy individuals of an equivalent age. Examinations for cranial nerve, deep tendon reflex, sensory, and coordination function revealed unremarkable results. She had no hepatosplenomegaly, goitre, or skin hyperpigmentation.
Laboratory exams indicated elevated serum creatinine kinase (496 U/L), elevated aspartate aminotransferase (102 U/L), elevated resting serum lactate (4.7 mmol/L), and borderline elevated serum calcium (10.2 mg/dL) levels. Blood count, estimated glomerular filtration rate, serum electrolyte levels (including sodium, potassium, and magnesium), and thyroid function were unremarkable. An arterial blood gas test revealed no hypoxemia, hypercapnia, or acid–base problems. A nerve conduction study yielded no evidence of polyneuropathy. Electromyography demonstrated myopathic motor unit action potential with early recruitment pattern as well as no spontaneous activity in all sampled muscles in the four proximal and distal limbs. An aerobic forearm exercise test  revealed elevated mixed venous oxygen saturation after 3 min of aerobic exercise, suggesting defective oxidative metabolism in the muscles (Table 1). Muscle magnetic resonance imaging of the bilateral thighs was unremarkable. Muscle pathology of the right rectus femoris muscle suggested lipid storage myopathy (Fig. 2). Tandem mass spectrometry of serum acylcarnitine revealed elevated short-, medium-, and long-chain acylcarnitines with secondary carnitine deficiency (Fig. 1d). Urine organic acid analysis indicated glutaric aciduria. ETFDH gene analysis revealed compound heterozygous mutations c.250G > A / p.Ala84Thr and c.524G > T / p.Arg175Leu. Both variants have previously been reported to be pathogenic [1, 3]. MADD was therefore diagnosed. We treated the patient with riboflavin, carnitine, and ubiquinone, and her symptoms rapidly improved. She was able to walk without assistance within 2 weeks, and she became asymptomatic within 3 months.
Discussion and conclusions
MADD is a lipid metabolism disorder that is caused by defects in electron transfer flavoprotein, which is encoded by ETFA and ETFB, or defects in electron transfer flavoprotein dehydrogenase, encoded by the ETFDH. Electron transfer flavoprotein and electron transfer flavoprotein dehydrogenase are located on the matrix face of the inner mitochondrial membrane and are involved in the oxidation of fatty acids. The aforementioned defects disturb electron transfer from acyl-CoA dehydrogenase (ACAD) through flavoproteins to ubiquinone and finally result in an accumulation of acyl-CoA of various chain lengths.
Late-onset MADD typically presents as lipid storage myopathy and episodic metabolic crisis. The myopathy usually manifests as proximal muscle weakness. Cardiomyopathy and respiratory insufficiency have also been reported. Metabolic crisis typically manifests as the exacerbation of weakness, lethargy, vomiting, hypoketotic hypoglycaemia, and metabolic acidosis. Common precipitating factors of acute exacerbation include prolonged fasting or physical stress such as exercise or infection . To date, antiobesity drugs have not been reported as a provoking factor. Regarding the possible mechanisms by which the drugs induced metabolic crisis, this report supports the hypothetical model of substrate competition in disorders involving β-oxidation dysfunction. In the substrate competition model of fatty acid oxidation, the accumulation of acyl-CoA of a certain chain length acts as competitive inhibitor of ACADs of different chain lengths . Therefore, the accumulation of acyl-CoA with multiple chain lengths exacerbates the dysfunction of multiple ACADs and forms the basis of metabolic crisis . Moreover, coenzyme A may be trapped as acyl-CoA and lead to dysfunction of glucose metabolism, which results in profound energy failure . Chokchaiwong et al. studied the mitochondrial bioenergetics of cells with ETFDH mutation and observed reduced mitochondrial membrane potential upon fatty acid challenge, supporting the concept of substrate competition in vitro; these researchers also reported decreased mRNA and protein levels of ETFDH upon fatty acid challenge, suggesting a complex negative feedback loop governing the pathophysiology of metabolic crisis .
Antiobesity drugs accelerate lipid catabolism. Microcosmically, they act comparably to a fatty acid challenge towards mitochondria, as in the aforementioned in vitro cell model. Metformin, one of our patient’s antiobesity drugs, is an electron transport chain complex I inhibitor, which activates AMP-activated protein kinase (AMPK) by increasing the AMP:ATP ratio. The AMPK pathway accelerates fatty acid transportation into mitochondria, which is typically the rate-limiting step of fatty acid oxidation . Thyroid hormone directly enhances lipid oxidation by increasing AMPK pathway activity, carnitine palmitoyl transferase activity, flavin adenine dinucleotide-linked respiratory pathway activity, and mitochondrial trifunctional protein activity . Topiramate increases fatty acid oxidation by increasing lipoprotein lipase activity and adiponectin levels and thus AMPK pathway activity . Taken together, the results indicate that the acute exacerbation of muscle strength after antiobesity drug use likely resulted from an overload of fatty acid oxidation at multiple steps in a suboptimal lipid metabolism system. This supports the notion of substrate competition.
This case report has two main strengths. First, this is the first reported case of a patient with MADD who had in vivo lipid challenge induced by medication, which supports the substrate competition model. Second, the diagnosis in this case was comprehensively confirmed through genetic and metabolic diagnosis, and complete improvement after treatment was verified. Nevertheless, this report has two limitations. First, the patient used multiple antiobesity drugs simultaneously; thus, inferring which drug contributed most to the exacerbation is challenging. Second, reproducing the exacerbation episode was infeasible for ethical reasons.
The medications this patient used, including metformin, thyroid hormone, and topiramate, are commonly used in clinical practice and can affect lipid metabolism, resulting in acute decompensation in patients with MADD. Thus, we report this case to increase the vigilance and proactivity of clinicians in recognising this treatable form of adult-onset myopathy.
Availability of data and materials
Data sharing is not applicable to this article because no datasets were generated or analysed in the current study.
Multiple acyl-CoA dehydrogenase deficiency
AMP-activated protein kinase
Er TK, Liang WC, Chang JG, Jong YJ. High resolution melting analysis facilitates mutation screening of ETFDH gene: applications in riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency. Clin Chim Acta. 2010;411(9–10):690–9.
Meulemans A, Gerlo E, Seneca S, Lissens W, Smet J, Van Coster R, et al. The aerobic forearm exercise test, a non-invasive tool to screen for mitochondrial disorders. Acta Neurol Belg. 2007;107(3):78–83.
Liang WC, Ohkuma A, Hayashi YK, Lopez LC, Hirano M, Nonaka I, et al. ETFDH mutations, CoQ10 levels, and respiratory chain activities in patients with riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency. Neuromuscul Disord. 2009;19(3):212–6.
Liang WC, Nishino I. State of the art in muscle lipid diseases. Acta Myol. 2010;29(2):351–6.
van Eunen K, Simons SM, Gerding A, Bleeker A, den Besten G, Touw CM, et al. Biochemical competition makes fatty-acid beta-oxidation vulnerable to substrate overload. PLoS Comput Biol. 2013;9(8):e1003186.
van Eunen K, Volker-Touw CM, Gerding A, Bleeker A, Wolters JC, van Rijt WJ, et al. Living on the edge: substrate competition explains loss of robustness in mitochondrial fatty-acid oxidation disorders. BMC Biol. 2016;14(1):107.
Mitchell GA, Gauthier N, Lesimple A, Wang SP, Mamer O, Qureshi I. Hereditary and acquired diseases of acyl-coenzyme a metabolism. Mol Genet Metab. 2008;94(1):4–15.
Chokchaiwong S, Kuo YT, Hsu SP, Hsu YC, Lin SH, Zhong WB, et al. ETF-QO Mutants Uncoupled Fatty Acid beta-Oxidation and Mitochondrial Bioenergetics Leading to Lipid Pathology. Cells. 2019;8(2):106.
Yerevanian A, Soukas AA. Metformin: Mechanisms in Human Obesity and Weight Loss. Curr Obes Rep. 2019;8(2):156–64.
Sayre NL, Lechleiter JD. Fatty acid metabolism and thyroid hormones. Curr Trends Endocinol. 2012;6:65–76.
Verrotti A, Scaparrotta A, Agostinelli S, Di Pillo S, Chiarelli F, Grosso S. Topiramate-induced weight loss: a review. Epilepsy Res. 2011;95(3):189–99.
We thank Professor Chou-Ching Lin for providing assistance in caring for the patient.
No targeted funding is reported.
Ethics approval and consent to participate
The manuscript was reviewed and approved by the Institutional Review Board of National Cheng Kung University Hospital for publication (IRB Approval No. A-EC-108-009).
Consent for publication
The manuscript was reviewed and approved by the Institutional Review Board of National Cheng Kung University Hospital for publication (IRB Approval No. A-EC-108-009). Written informed consent was obtained from the patient.
The authors declare no competing interests.
About this article
Cite this article
Lin, PY., Liang, WC., Liao, WA. et al. Exacerbation of myopathy triggered by antiobesity drugs in a patient with multiple acyl-CoA dehydrogenase deficiency. BMC Neurol 21, 93 (2021). https://doi.org/10.1186/s12883-021-02121-y
- Multiple acyl-coA dehydrogenase deficiency
- Thyroid hormones